
A
ACR20
ACR50
ACR70
% Patients
80
60
40
20
0
57
29
0
75
56
25
Placebo (n=7)
Cohort H (3 mg/kg SC) (n=16)
B
Median DAS28-CRP
7
6
5
4
3
2
5.69
4.94
5.45
4.86
4.91
4.66
5.44
4.42
3.76
3.47
3.62
4.06
Placebo
Cohort H (3 mg/kg SC) (n=16)
Week 0 2 4 6 8 10
C
% C-Reactive Protein Reduction
35
30
25
20
15
10
5
0
8.4
28.3
Placebo (n=7)
Cohort H (3 mg/kg SC) (n=16)
D
% Patients with ACR50 Response
70
60
50
40
30
20
10
0
Placebo (n=7)
Cohort H (3 mg/kg SC) (n=16)
14
12
14
31
29
56
29
56
14
50
Week 2 4 6 8 10